тепловизор дедал т2 380 хантер цена от производителя
Главное меню:
Интересное
тепловизор дедал т2 380 хантер цена от производителя, Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced , Lost in translation: Revisiting the use of tyrosine kinase inhibitors , Combination IO/TKI Strategies in Metastatic Colorectal Cancer, A real-world study: third-line treatment options for metastatic , Protocol: Evaluation of tyrosine kinase inhibitors combined with , (PDF) Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for , Treatment of Metastatic Colorectal Cancer: Beyond Progression.
Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine/tipiracil (TAS-102), but these drugs have limited clinical efficacy. This study aims to evaluate the efficacy and survival outcomes of tyrosine kinase inhibitor (TKI) versus chemotherapy rechallenge in third-line treatment for advanced mCRC patients. From January 2019 to December 2022, 107 patients met the inclusion criteria. After 1:1 matching, there were 34 patients in both the TKI and rechallenge groups. Cox regression analysis was performed to identify independent predictive factors. The result indicated that Eastern Cooperative Oncology Group (ECOG) score of 0-1 (hazard ratio [HR] = 0.03, 95% confidence interval [CI]: 0.01-0.17; P < 0.001) and chemotherapy rechallenge (HR = 0.43, 95% CI: 0.23-0.79; P = 0.007) were independent protective factors for overall survival (OS). Patient-Generated Subjective Global Assessment (PG-SGA) score of 0-3 (HR = 0.43, 95% CI: 0.23-0.80; P = 0.008), progression-free survival (PFS) of frontline treatment (HR = 0.66, 95% CI: 0.43-1.00, P = 0.047) and chemotherapy rechallenge (HR = 0.42, 95% CI: 0.24-0.73; P = 0.002) were independent protective factors for PFS. Kaplan-Meier survival analysis showed that the median OS in the rechallenge group was 13.2 months (95% CI: 9.6-19.3), compared with 7.7 months (95% CI: 6.5-14.5) in the TKI group, with a statistically significant difference (HR = 0.47, 95% CI: 0.26-0.86; P = 0.013). The median PFS for the rechallenge group was 5.0 months (95% CI: 4.3-6.7), compared with 3.4 months (95% CI: 2.7-4.8) in the TKI group, with a statistically significant difference too (HR = 0.54, 95% CI: 0.32-0.91; P = 0.019). Furthermore, subgroup analysis showed that in Group A, the rechallenge group also had superior median OS and PFS compared with the TKI group. In conclusion, while TKIs are the current standard for third-line treatment in mCRC patients, chemotherapy rechallenge is a more effective option for patients who have achieved disease control in the first two lines of treatment., Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine/tipiracil (TAS-102), but these drugs have limited clinical efficacy. This study aims to evaluate the efficacy and survival outcomes of tyrosine ki …, Patients with advanced or metastatic colorectal cancer ( (m)CRC) have limited effective treatment options resulting in high mortality rates. A better understanding of the molecular basis of this disease has led to growing interest in small molecule tyrosine kinase inhibitors (TKIs) for its treatment..
A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer., Abstract Background Numerous third-line treatment options exist for colorectal cancer. This study aims to assess the efficacy and safety of third-line therapies, including TKIs (fruquintinib, regorafenib) combined with PD-1 inhibitors, and trifluridine/tipiracil combined with bevacizumab, in patients with refractory microsatellite stable metastatic colorectal cancer who have progressed or are , This is the first study to try to evaluate the efficacy and safety of tyrosine kinase inhibitors (TKIs) in combination with antiprogrammed cell death protein 1 (anti-PD-1) antibody in TKI-responsive patients with microsatellite stable/proficient mismatch repair (MSS/pMMR) metastatic colorectal adenocarcinoma (mCRC)., PDF | Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and | Find, read and cite all the research you , New therapeutic options, immune checkpoint inhibitors, monoclonal antibodies against various targets, and multitargeted tyrosine kinase inhibitors are available in the treatment of later lines of metastatic colorectal cancer. The treatment strategy is based on patients’ performance status, residual toxicity, and especially molecular profile., This study aims to evaluate the efficacy and survival outcomes of tyrosine kinase inhibitor (TKI) versus chemotherapy rechallenge in third-line treatment for advanced mCRC patients..